WO2003023398A1 - Method of screening drug and method of judging significance of mutation in gene encoding transcriptional regulatory factor - Google Patents

Method of screening drug and method of judging significance of mutation in gene encoding transcriptional regulatory factor Download PDF

Info

Publication number
WO2003023398A1
WO2003023398A1 PCT/JP2002/002171 JP0202171W WO03023398A1 WO 2003023398 A1 WO2003023398 A1 WO 2003023398A1 JP 0202171 W JP0202171 W JP 0202171W WO 03023398 A1 WO03023398 A1 WO 03023398A1
Authority
WO
WIPO (PCT)
Prior art keywords
remedies
transcriptional regulatory
regulatory factor
mutation
gene encoding
Prior art date
Application number
PCT/JP2002/002171
Other languages
French (fr)
Japanese (ja)
Inventor
Tahir Tahirov
Kazuhiro Ogata
Original Assignee
The Kanagawa Academy Of Science And Technology Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP2001274161A external-priority patent/JP2003079400A/en
Priority claimed from JP2001274021A external-priority patent/JP2003083963A/en
Application filed by The Kanagawa Academy Of Science And Technology Foundation filed Critical The Kanagawa Academy Of Science And Technology Foundation
Publication of WO2003023398A1 publication Critical patent/WO2003023398A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A method whereby a compound which is expected as showing a drug effect via the inhibition or regulation of a transcriptional regulatory factor can be screened without using any animals or cells in the test. By this drug screening method, a substance capable of binding to the minor groove of DNA is screened. This method is useful as a primary screening method for immunomodulators, antiviral agents, antiinflammatory agents, remedies for arteriosclerosis, anticancer agents, remedies for hypertension, remedies for diabetics, remedies for failure in infection protective mechanism, etc.
PCT/JP2002/002171 2001-09-10 2002-03-08 Method of screening drug and method of judging significance of mutation in gene encoding transcriptional regulatory factor WO2003023398A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2001-274161 2001-09-10
JP2001-274021 2001-09-10
JP2001274161A JP2003079400A (en) 2001-09-10 2001-09-10 Method for evaluation of significance of mutation in gene cording transcription factor protein
JP2001274021A JP2003083963A (en) 2001-09-10 2001-09-10 Medicine screening method

Publications (1)

Publication Number Publication Date
WO2003023398A1 true WO2003023398A1 (en) 2003-03-20

Family

ID=26621936

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/002171 WO2003023398A1 (en) 2001-09-10 2002-03-08 Method of screening drug and method of judging significance of mutation in gene encoding transcriptional regulatory factor

Country Status (1)

Country Link
WO (1) WO2003023398A1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05505241A (en) * 1990-06-27 1993-08-05 プリンストン ユニバーシティ Mutant p53 detection probe
JPH1183857A (en) * 1997-09-05 1999-03-26 Dainippon Printing Co Ltd Lamination body for optical analyzer measurement chip
JP2001103981A (en) * 1999-08-03 2001-04-17 Nisshinbo Ind Inc Kit for diagnosing mycobacterium tuberculosis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05505241A (en) * 1990-06-27 1993-08-05 プリンストン ユニバーシティ Mutant p53 detection probe
JPH1183857A (en) * 1997-09-05 1999-03-26 Dainippon Printing Co Ltd Lamination body for optical analyzer measurement chip
JP2001103981A (en) * 1999-08-03 2001-04-17 Nisshinbo Ind Inc Kit for diagnosing mycobacterium tuberculosis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Alexnder L. Satz, et al., "Double-Stranded DNA Binding Characteristics and Subcellular Distribution of a Minor Groove Binding Diphenyl Ether Bisbenzimidazole", Biochemistry, 40, 6465-6474, 2000. *
Cristine M. White, et al., "Evaluation of the Effectiveness of DNA-Binding Drugs to Inhibit Transcription Using the c-fos Serum Response Element as a Target", Biochemistry, 39, 12262-12273, 2000. *

Similar Documents

Publication Publication Date Title
DE502005007840D1 (en) 7-PHENYLAMINO-4-CHINOLONE-3-CARBOXYLIC ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS
WO2006079021A3 (en) Use of sirtuin-activating compounds for treating flushing and drug induced weight gain
DE50306845D1 (en) DISUBSTITUTED THIAZOLYL CARBOXANILIDES AND THEIR USE AS MICROBICIDES
DE502004011957D1 (en) NEW CYANOPYRROLIDIDES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS
MY138838A (en) A pharmaceutical composition comprising a combination of valsartan, amlodipine and hydrochlorothiazide
ATE348609T1 (en) TETRAHYDRONAPHTHALINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS ANTI-INFLAMMATORY
ATE302754T1 (en) SULFONYLCARBOXAMIDE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICINAL PRODUCTS
WO2004075865A3 (en) Selective modulation of tlr-mediated biological activity
WO2004042002A3 (en) Compounds for modulating rna interference
WO2005007621A3 (en) Ubiquitin ligase inhibitors
WO2006009765A3 (en) Methods for the identification and use of compounds suitable for the treatment of drug resistant cancer cells
ATE396190T1 (en) SUBSTITUTED HETEROARYLALKANEOUS ACID AND THEREOF USE AS INHIBITORS OF ALDOSE REDUCTASE
DE10393704D2 (en) Nancomposites, process for their preparation and their use
DE602006019731D1 (en) 2,6-CHINOLINE DERIVATIVES AND METHOD FOR THEIR PREPARATION AND USE AS MEDICAMENTS
DE60336264D1 (en) INDIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS AND INTERMEDIATE PRODUCTS AND METHODS FOR THEIR MANUFACTURE
DE50207011D1 (en) ARYLISOXAZOLINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS PESTICIDES
ATE407929T1 (en) BICYCLIC HETEROCYCLES, MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS, THEIR USE AND METHOD FOR THEIR PRODUCTION
ATE473738T1 (en) 1-SULFONYLINDOL DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS 5-HT6 LIGANDS
ATE389654T1 (en) CYCLOALKYL SUBSTITUTED 7-AMINO-4-QUINOLONE-3-CARBOXYLIC ACID DERIVATIVES, METHOD FOR THEIR PRODUCTION AND THEIR USE AS MEDICINAL PRODUCTS
ATE384069T1 (en) ALKYLIDENE-TETRAHYDRONAPHTHALINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS ANTI-INFLAMMATORY
WO2000051987A3 (en) Inhibitors of advanced, post-amadori glycosylation reactions
ATE304534T1 (en) AMINOCARBONYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICINAL PRODUCTS
WO2003023398A1 (en) Method of screening drug and method of judging significance of mutation in gene encoding transcriptional regulatory factor
ATE302765T1 (en) 2-ARYLIMINO-2,3-DIHYDROTHIAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR THERAPEUTIC USE
WO2001041709A3 (en) Methods for treating cell death diseases and inflammation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA